The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
COMMENTARY
New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the ruling Liberal Democratic Party (LDP) and its coalition partner Komeito. The bill embraces the launch of a new government fund…
To read the full story
Related Article
- Japan Cabinet Approves Bill to Amend PMD Act
February 13, 2025
- PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official
February 4, 2025
- LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
January 28, 2025
- Drug Discovery Fund Not Mentioned in Ruling Party Document; All Eyes on Bill’s Review on Jan. 27
January 24, 2025
- MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting
January 24, 2025
- Draft Bill to Amend PMD Act Up for LDP Review on Jan. 27
January 23, 2025
- Nothing Decided on Drug Discovery Support Fund: Minister
January 15, 2025
- FPMAJ Chair Calls for Sufficient Consensus on Drug Discovery Support Fund
January 7, 2025
- PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
December 26, 2024
COMMENTARY
- Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
March 4, 2025
- New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
- Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
February 5, 2025
- Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
January 27, 2025
- Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies
January 9, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…